Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1IIT A Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of XP-001-V2 in Patients with Advanced Solid Tumors
/ Not yet recruitingPhase 1 一项评价XP-001-V2在晚期实体瘤患者中的安全性、耐受性和初步疗效的Ⅰ期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability and preliminary efficacy of XP-001-V2 in patients with advanced solid tumors
评价XP-001-V2的安全性、耐受性和初步疗效,为后续临床研究设计提供合理依据。
[Translation] Evaluate the safety, tolerability and preliminary efficacy of XP-001-V2 and provide a reasonable basis for the design of subsequent clinical studies.
100 Clinical Results associated with Shanghai Xinpu Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Xinpu Biomedical Technology Co., Ltd.
100 Deals associated with Shanghai Xinpu Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Xinpu Biomedical Technology Co., Ltd.